Stocks in play: Eupraxia Pharmaceuticals Inc.
Announced positive clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc. shares T.EPRX are trading up $0.34 at $6.07.
Read:
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer
Tech Titans Battle for Supremacy in the $1.3 Trillion Generative AI Marketplace
300,000 New Cases: The Role of Biotech in Addressing Rising Breast Cancer Rates
Lithium Developers Moving Forward on Domestic Projects Despite Pushback from Opponents